Mirtazapine

CLINICAL USE

Antidepressant

DOSE IN NORMAL RENAL FUNCTION

15–45 mg daily in 1 or 2 divided doses

PHARMACOKINETICS

Molecular weight :265.4

%Protein binding :85

%Excreted unchanged in urine : 75

Volume of distribution (L/kg) :107 litres

half-life – normal/ESRD (hrs) :20–40/Increased

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Start at low dose and monitor closely

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unlikely to be dialysed. Dose as in GFR <10 mL/min

HD :Unlikely to be dialysed. Dose as in GFR <10 mL/min

HDF/high flux :Unknown dialysability. Dose as in GFR <10 mL/min

CAV/VVHD :Unlikely to be dialysed. Dose as in GFR 10 to 20 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Alcohol: increased sedative effect

Antidepressants: CNS excitation and hypertension with MAOI and moclobemide – avoid concomitant use

Antimalarials: avoid concomitant use with artemether and lumefantrine

Sibutramine: increased risk of CNS toxicity – avoid concomitant use

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–.

Tags: post-by-auto-php